Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo

DOMINGUEZ-MEIJIDE, ANTONIO; PARRALES, VALERIA; VASILI, EFTYCHIA; GONZÁLEZ-LIZÁRRAGA, FLORENCIA; KÖNIG, ANNEKATRIN; LÁZARO, DIANA F.; LANNUZEL, ANNIE; HAIK, STÉPHANE; DEL BEL, ELAINE; CHEHÍN, ROSANA; RAISMAN-VOZARI, RITA; MICHEL, PATRICK P.; BIZAT, NICOLAS; OUTEIRO, TIAGO FLEMING

NEUROBIOLOGY OF DISEASE

ACADEMIC PRESS INC ELSEVIER SCIENCE

Año: 2021 vol. 151 p. 105256 - 105275

0969-9961

Parkinson´s disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders characterized by the misfolding and aggregation of alpha-synuclein (aSyn). Doxycycline, a tetracyclic antibiotic shows neuroprotective effects, initially proposed to be due to its anti-inflammatory properties. More recently, an additional mechanism by which doxycycline may exert its neuroprotective effects has been proposed as it has been shown that it inhibits amyloid aggregation. Here, we studied the effects of doxycycline on aSyn aggregation in vivo, in vitro and in a cell free system using real-time quaking induced conversion (RT-QuiC). Using H4, SH-SY5Y and HEK293 cells, we found that doxycycline decreases the number and size of aSyn aggregates in cells. In addition, doxycycline inhibits the aggregation and seeding of recombinant aSyn, and attenuates the production of mitochondrial-derived reactive oxygen species. Finally, we found that doxycycline induces a cellular redistribution of aggregates in a C.elegans animal model of PD, an effect that is associated with a recovery of dopaminergic function. In summary, we provide strong evidence that doxycycline treatment may be an effective strategy against synucleinopathies.